Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
Executive Summary
Novel approvals by US FDA in 2017 could easily surpass the 28 agents approved by the agency's drug and biologics centers in 2016. The big question is whether last year's spike in complete response letters was an anomaly or the start of a trend.
You may also be interested in...
New Active Substance Launches Declined Again In 2016
2016 witnessed a second straight year of decline in the number of new active substance launches worldwide, but trend data show that this hard measure of R&D productivity was still healthy compared with industry's performance during the first decade of the century.
Pharma's First Quarter: Approvals, Successes and Setbacks
As public companies prepare to present their financial reports for the first quarter of 2017, Scrip has gathered the stats on drug approvals for the first three months, as well as highlights of the biggest trial success and most disappointing clinical setbacks of this year so far.
Keeping Track: US FDA Files Another Pfizer Cancer Biologic And TMC's New Antibiotic
The latest drug development news and highlights from our FDA Performance Tracker.